Context.-Almost all cervical cancers are related to the human papillomavirus (HPV). Future strategies for cervical cancer screening will be based on HPV detection. The Hybrid Capture 2 (HC2) test is currently the most widely used method to screen for HPV.
assays was 91.7% (802 of 875; j ¼ 0.743; 95% confidence interval, 0.688-0.798). The noninferiority score test (relative sensitivity of 90%, T ¼ 2.85, P ¼ .002; and relative specificity of 98%, T ¼ 2.75, P ¼ .003) demonstrated that the Cervista results were not inferior to those of the HC2 test. Intralaboratory and interlaboratory reproducibility was determined by evaluating 513 and 507 samples, respectively. These reproducibilities showed j values of 0.886 (95% confidence interval, 0.845-0.927) and 0.907 (95% confidence interval, 0.886-0.948), respectively.
Conclusions.-Our results demonstrate that the Cervista HPV HR test shows the same specificity as the HC2 assay. We therefore conclude that the Cervista HPV HR test is suitable for cervical cancer screening purposes.
(Arch Pathol Lab Med. 2015;139:241-244; doi: 10.5858/ arpa.2014-0012-OA) N early all cervical cancers are related to the human papillomavirus (HPV). Persistent cervical infection with certain types of HPV is a prerequisite for the development of cervical cancer through precursor lesion, namely, cervical intraepithelial neoplasia (CIN) 3.
1,2 The most important carcinogenic HPV genotypes are HPV16 and HPV18. The detection of high-risk HPV (HR HPV) in cervical samples, together with abnormal cytologic findings, is crucial in cervical cancer screening. 3 It is essential to improve screening strategies to avoid unnecessary clinical follow-up, diagnostic procedures, and treatment of healthy women. 4 In Catalonia, the HPV test has been used in the cervical cancer screening protocol since 2006 as a complementary test to cytology in 3 circumstances: atypia on squamous cells of undetermined significance, monitoring after treatment for high-grade CIN (CIN 2þ), and screening of women older than 40 years who have not had a cytologic test in the previous 5 years.
Hybrid Capture 2 (HC2; Qiagen, Hilden, Germany) is currently the most widely used HPV method to determine the presence of HR HPV in cytologic samples. It shows greater clinical sensitivity than other methods and acceptable specificity. 5, 6 A group of experts in 2009 published recommendations for the validation of new techniques for the detection of HR HPV in cervical samples. Those guidelines stated that candidate HPV tests should be comparable in clinical sensitivity and specificity with HC2 for the detection of CIN 2þ in women older than 30 years, using the HC2 test result as the gold standard. New tests should demonstrate at least 90% sensitivity and 98% specificity of the HC2 results, as assessed by a noninferiority score test. 7, 8 In this regard, here we evaluated the performance of the Food and Drug Administration-approved 9 Cervista HPV HR test (Hologic, Bedford, Massachusetts).
MATERIALS AND METHODS

Clinical Specimens
The Pathology Department of the Hospital del Mar is a reference laboratory for cervical cytology in an area with a population of approximately 150 000 women, of whom 105 000 (70%) are 30 years or older. On completion of cytologic and HPV testing by HC2, the samples with a minimum of 10 mL of PreservCyt (Hologic) were identified for inclusion in the study.
From a total of 1125 consecutive samples received by the Pathology Department between October 2011 and March 2012, 875 cervical samples were included in the study. To examine the sensitivity of the Cervista HPV HR test, we included 64 samples from women with a biopsy of CIN 2þ or higher, with simultaneous or previous cytology (maximum of 3 months before diagnosis). To study the specificity of the Cervista test, we used 811 samples from women with one of the following cytology results: negative (n ¼ 715), atypia on squamous cells of undetermined significance (n ¼ 64), low-grade squamous intraepithelial lesion (n ¼ 31), or atypia of squamous cells suspicious of high-grade lesion (n ¼ 1), with a biopsy less than CIN 2 or without a biopsy. We attempted to consider the annual statistical distribution of age and cytology diagnosis of the department. Age was not an exclusion criterion in this study.
The project was approved by the PSMar Ethics Committee (2011/ 4468I).
Papanicolaou Tests and Cervical Cytology
The samples were collected using ThinPrep (Hologic) vials with 20 mL of PreservCyt, and a slide for the cytologic study was made. The cervical cytologic examination was performed using the automated Imager system (Hologic) and reviewed by experienced cytotechnologists and cytopathologists. The results were reported following the Bethesda 2001 system.
10
HC2 HR HPV DNA Test
The remaining material was first used for the HC2 test (4 mL for each measurement). This is an isothermal signal-amplification method that detects a total of 13 HR HPV subtypes (16, 18 , 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) in cytology samples. The DNA-RNA hybrids are formed when there is sufficient genetic viral material detected by antihybrid antibodies. The final enzymatic reaction produces a luminescent signal, which is measured automatically by a luminometer. We used 1 pg/mL as the cutoff for HPV DNA. The result is reported as positive or negative with a semiquantitative value in relative light units (RLUs). 11 
Cervista HPV HR Test
The remaining material was used to perform the Cervista test (2 mL for each measurement). This test is an automated method that detects 14 HR HPV subtypes simultaneously in 3 different mixes (mix 1: 51, 56, and 66; mix 2: 18, 39, 45, 59, and 68; and mix 3: 16, 31, 33, 35, 52, and 58). In this procedure, first the Gendfind kit (Hologic) is used to extract DNA, and the Cervista test then uses Invader (Hologic) chemistry, which comprises two simultaneous isothermal and signal-amplification reactions to detect specific nucleic acid sequences. The test is based on the enzymatic reaction catalyzed by the Cleavase (Hologic) enzyme, which is a 5 0 flap endonuclease enzyme. A primary reaction occurs on the targeted DNA sequence, and the secondary reaction produces a fluorescent signal.
9,12
Intralaboratory and Interlaboratory Tests
The intralaboratory and interlaboratory reproducibility was determined by evaluating 507 and 513 samples, respectively. At least 30% of the cases used for these comparisons were HC2þ. The interlaboratory test was performed in a laboratory in Portugal (Laboratorio de Anatomia Patologica in Porto).
Linear Array Test Genotyping Test
Discordant cases were studied by the linear array test genotyping test. This test is based on a polymerase chain reaction amplification followed by hybridization using a ''reverse line blot system,'' which simultaneously detects 37 HPV strains ( ). The test amplifies a 450-bp region from the L1 gene, using a pool of PGMY (PG MY09-MY11 primers), as well as an internal control based on beta globin amplification. After the hybridization, the result is interpreted with a reference guide.
Statistical Study
The results from the Cervista test were compared with those from HC2 by means of a noninferiority score test. The Cervista test should reach at least 90% and 98% of the sensitivity and specificity, respectively, of the HC2 test. The agreement between the tests must be moderate/good, with a j value of 0.7. 
RESULTS
The mean age of the 875 patients was 44.8 years (range, 17-86 years), whereas patients with CIN 2þ had a mean age of 32.13 years (range, 18-74 years). The percentage of women 
; 56.2%) cases. Analysis of the sensitivity and specificity for CIN 2 or higher samples using the Cervista test compared with the gold standard HC2 by noninferiority score tests showed that the performance of the new test was not inferior (relative sensitivity of 90%, T ¼ 2.85, P ¼ .002; and relative specificity of 98%, T ¼ 2.75, P ¼ .003).
The intralaboratory reproducibility showed a j value of 0.886 (95% CI, 0.845-0.927), with 26 discordant results in 507 cases (5.2%; Table 2 ). The interlaboratory reproducibility showed a j value of 0.907 (95% CI, 0.886-0.948), with only 18 cases of 513 (3.5%) showing discordance ( Table 2) .
A comparison of the results of the 2 tests showed statistically significant differences between women with or without high-grade squamous intraepithelial lesion (HSIL; 
COMMENT The detection of HR HPV in cervical samples, together with abnormal cytologic findings, is crucial for cervical cancer screening. Some studies have shown that HPV tests have a higher negative predictive value than negative cytology at 3 to 5 years. 13, 14 However, the sole use of HPV testing in cervical cancer screening may lead to unnecessary clinical follow-up, diagnostic procedures, or treatment in healthy women. HC2 was the first method approved by the Food and Drug Administration for the detection of HPV DNA. However, this technique has some limitations, such as false-positive results-which may be due to crossreactivity with low-risk HPV DNA-and also the high requirements of sample volume (4 mL) for adequate results. Therefore, there is a continuing need to validate new HPV tests 3 that can contribute to minimizing redundant or excessive follow-up procedures. This is the first study to apply the Cervista HPV HR test in the Catalonian population. This test involves a new technology based on novel molecular reagents, and it uses Invader chemistry to detect HR HPV DNA in cervical samples. Meijer et al 7 recommended studies based on a population of women with a recommended age of older than 30 years. In our study, 10.5% (92 of 875) of the cohort was younger than 30 years.
Regarding laboratory productivity, the Cervista test provides 4 hours of autonomy time, and the results can be read within 24 hours of completing the test. In contrast, those produced by HC2 must be read in the 15 to 30 minutes following the test. The Cervista test also includes a specific internal control for DNA quality testing, and thus has the advantage that it decreases the number of falsenegative results. The lower requirement of sample material for the Cervista test (2 mL versus 4 mL for HC2) is another advantage for the clinical laboratory, and this test may be useful for additional assays. 7 Another important feature is that it requires DNA extraction. In contrast to the denatured samples used in the HC2 process, the extracted DNA can be stored and used in further studies, like HPV genotyping.
Regarding the sensitivity and specificity, the Cervista test showed excellent results, as reported in the literature. 9, 15, 16 The analytic agreement with HC2 was very high (91.7%). Clinical sensitivity and specificity showed noninferiority in comparison with HC2, the gold standard method. Furthermore, the intralaboratory and interlaboratory reproducibility was very high, showing the minimal requirements for a clinical test. These results indicate that the Cervista test has the same clinical value as that of HC2.
The values of the results found for the 2 tests can be attributed to viral load, but in no case a quantitative viral load. A comparison of the results of HC2 and those of the Cervista test showed statistically significant differences in HC2 RLUs and Cervista fold-over-zero (FOZ) values for women with or without HSIL. That is to say, samples with ''no HSIL'' showed significantly lower values by both methods in comparison with HSIL samples. Factors like the extent of the lesions, the number of HPV types, and the number of atypia on squamous cells of undetermined significance/low-grade squamous intraepithelial lesion cells in cytology cervical samples vary greatly among CIN 3 cases, as demonstrated by Sherman et al. 17 These issues strongly affect HPV load and consequently limit the clinical use of load measurements, regardless of the HPV testing methodology applied.
The comparison between concordant (HC2
cases showed statistically significant differences. That is, discordant cases showed significantly lower values than concordant cases. The lower values could explain the differences between the 2 techniques that arise as a result of the closeness to cutoff values. Data collected from the Cervista test were divided into positive or negative, with a defined cutoff. The falsepositive cases by the Cervista test may be due to the cutoff applied. A higher cutoff may reduce false-positive cases detected by this test and improve the sensitivity and specificity of this method.
Regarding false-negative cases by the Cervista test, the limitation of HC2 as a result of cross-reactivity with low-risk HPV DNA is well known. This would be the next step to determine the true benefit of the Cervista test in low-risk HPV DNA cases. A more detailed analysis of discordant results using other techniques may provide further insight into the small differences between tests. However, this information may prove to be irrelevant from a clinical point of view, because the two tests shared a sensitivity higher than 95% and a specificity higher than 85%. Furthermore, our data show that no HSIL cases appeared in the follow-up of discordant cases.
In conclusion, our results demonstrate that the Cervista HPV HR test performs equally as well as HC2. Moreover, it has the advantage that it includes some benefits for the laboratory. For example, it includes an internal control, it has lower requirements of sample material, and it involves hands-free time. 
